TY - JOUR
T1 - Potential Site to Direct Selective Compounds in the Triosephosphate Isomerase for the Development of New Drugs
AU - Benítez-Cardoza, Claudia G.
AU - Jiménez-Pineda, Albertana
AU - Angles-Falconi, Sergio I.
AU - Fernández-Velasco, Daniel A.
AU - Vique-Sánchez, José L.
N1 - Publisher Copyright:
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2020/4/30
Y1 - 2020/4/30
N2 - In the pharmaceutical industry, the development of selective drugs to an enzyme or the repositioning of commercial drugs, today, is booming. The glycolytic enzyme triosephosphate isomerase (TIM) has been used as a therapeutic target for the development of new drugs against various pathogenic organisms. Therefore, saving resources in the development of new drugs, by directing the interaction of pharmacological compounds to an interaction site with a high probability to be selective, represents an opportunity for researchers.
AB - In the pharmaceutical industry, the development of selective drugs to an enzyme or the repositioning of commercial drugs, today, is booming. The glycolytic enzyme triosephosphate isomerase (TIM) has been used as a therapeutic target for the development of new drugs against various pathogenic organisms. Therefore, saving resources in the development of new drugs, by directing the interaction of pharmacological compounds to an interaction site with a high probability to be selective, represents an opportunity for researchers.
KW - Docking
KW - Drug design
KW - Inhibitors
KW - Triosephosphate isomerase
UR - http://www.scopus.com/inward/record.url?scp=85090996221&partnerID=8YFLogxK
U2 - 10.1002/slct.202000820
DO - 10.1002/slct.202000820
M3 - Artículo
AN - SCOPUS:85090996221
SN - 2365-6549
VL - 5
SP - 4866
EP - 4874
JO - ChemistrySelect
JF - ChemistrySelect
IS - 16
ER -